The New York University School of Medicine has a long established record of training academic hematologists. In large part, this record has been fostered by the continuous support, since 1962, of a NIH Training Grant (T32) which supports 6 M.D., M.D., PhD, and PhD Trainees. The long term goal of the Training Program is to prepare Hematology Trainees for future careers in academic medicine. The interaction of both M.D., M.D./ PhD, and PhD Trainees in a unified Training Program serves to increase the number of physicians and scientists committed to a career in research. The Training Program exposes Trainees to rigorous mentored lab based hematology research, a detailed curriculum, seminar series, a journal club,a clinical management conference, and the opportunity to participate (for M.D Trainees) or observe (for PhD Trainees) the practice of clinical hematology relevant to the Trainee's laboratory investigation. Trainees are selected from the ACGME accredited adult and pediatric hematology/medical oncology fellowship programs and from eligible post- doctoral PhD fellows in participating faculty member's laboratories. The program, led by a Director with three well qualified Associate Directors, is specifically dedicated to actively recruiting underrepresented minorities. Our 15 Mentors have experience in mentoring and documented productivity, and their laboratories are highly interactive and use a variety of model systems to study 1) benign hematology including PNH, platelet biology and Fanconi anemia;2) the genetics of leukemia;3) JAK/STAT and Ras signaling mechanisms in hematopoietic stem cells, lymphopoieis, leukemia and lymphoma;4) lymphopoiesis and lymphocyte activation (including GVHD);5) mechanisms of myeloid and lymphoid trafficking;6) ubiquitination in hematopoietic stem cell biology, lymphopoiesis, and leukemia/lymphoma;and 7) the epigenetic and molecular basis of normal and abnormal hematopoiesis. Past graduates of our program have achieved the highest ranks of academia and have made lasting contributions to the field of hematology, and a high proportion of our recent graduates remain in academia, using the research skills gained as Trainees in careers as researchers, academic teachers and trialists. Over the last 10 years the majority of our graduates have obtained positions in academic institutions, have published their findings in the highest tier of journals, and have received multiple NIH and foundation awards.
Hematological disorders represent a major cause of death in the U.S. Insights into many diseases have also come from laboratory-based research of hematological disorders and hematopoiesis. Well trained physicians and scientists will lead the way to new treatments for these disorders through fundamental and translational research, education, and clinical trials.
|Raetz, Elizabeth A; Morrison, Debra; Romanos-Sirakis, Eleny et al. (2014) A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leu J Pediatr Hematol Oncol 36:458-63|
|Xing, Weiman; Busino, Luca; Hinds, Thomas R et al. (2013) SCF(FBXL3) ubiquitin ligase targets cryptochromes at their cofactor pocket. Nature 496:64-8|
|Busino, Luca; Millman, Scott E; Scotto, Luigi et al. (2012) Fbxw7?- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 14:375-85|
|Ge, Sheng; Skaar, Jeffrey R; Pagano, Michele (2009) APC/C- and Mad2-mediated degradation of Cdc20 during spindle checkpoint activation. Cell Cycle 8:167-71|
|Sewak, Sanjeev; Sorich, Joan; O'Leary, James (2006) Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen. Anticancer Drugs 17:571-9|
|Pavlick, Anna C; Adams, Sylvia; Fink, Matthew A et al. (2003) Novel therapeutic agents under investigation for malignant melanoma. Expert Opin Investig Drugs 12:1545-58|
|Afonja, O; Smith Jr, J E; Cheng, D M et al. (2000) MEIS1 and HOXA7 genes in human acute myeloid leukemia. Leuk Res 24:849-55|
|Afonja, O; Amorosi, E; Ashman, L et al. (1998) Multilineage involvement and erythropoietin-"independent" erythroid progenitor cells in a patient with systemic mastocytosis. Ann Hematol 77:183-6|
|Smith, J E; Afonja, O; Yee, H T et al. (1997) Chromosomal mapping to 15q14 and expression analysis of the human MEIS2 homeobox gene. Mamm Genome 8:951-2|
|Jacobson, D R; Mills, N E (1994) A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia. Oncogene 9:553-63|
Showing the most recent 10 out of 16 publications